<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189202</url>
  </required_header>
  <id_info>
    <org_study_id>Steroid Avoidance in A.A.</org_study_id>
    <nct_id>NCT00189202</nct_id>
  </id_info>
  <brief_title>Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans</brief_title>
  <official_title>Efficacy of Sirolimus-Based, Steroid Avoidance Maintenance Immunosuppression in Black de Novo Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      African Americans receiving a kidney transplant are considered at high risk for early
      rejection of their transplanted kidney and require more immunosuppression to maintain their
      kidney transplant function. This increase in immunosuppression puts this group at risk for
      drug-related toxicities and complications such as post-transplant diabetes.

      This study will evaluate:

        1. Whether a sirolimus based steroid avoidance regimen in African Americans may decrease
           the risks of drug-related toxicities,

        2. Decreased rates of metabolic complications such as post-transplant diabetes,

        3. The effect of Sirolimus plus a reduced dose cyclosporine on renal allograft function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open labeled prospective trial with race matched historical controls. The
      treatment group (experimental arm) will be African American de novo solitary renal transplant
      recipients. The control arm will consist of race matched solitary renal transplant recipients
      who received a Cyclosporine (CsA) -based immunosuppressive regimen. The subjects will be
      matched for organ source (living donor vs. cadaveric). The experimental treatment arm will
      have an immunosuppression regimen consisting of Sirolimus, Reduced dose cyclosporine,
      Thymoglobulin, and only 3 doses of steroids.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 1, 2008</completion_date>
  <primary_completion_date type="Actual">July 1, 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative One-year Acute Rejection Rates</measure>
    <time_frame>12 months</time_frame>
    <description>To test the efficacy of Sirolimus (SRL)-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: cumulative one-year acute rejection rates of the transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>One-year Graft Survival</measure>
    <time_frame>12 months</time_frame>
    <description>To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year graft survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>One-year Patient Survival</measure>
    <time_frame>12 months</time_frame>
    <description>To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year patient survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post Transplant Diabetes</measure>
    <time_frame>12 months</time_frame>
    <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is incidence of posttransplant diabetes mellitus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-treated Dyslipidemic Syndrome</measure>
    <time_frame>12 months</time_frame>
    <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is drug-treated dyslipidemic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Control</measure>
    <time_frame>12 months</time_frame>
    <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is number of people who had their blood pressure in the target control range with or without medication</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Sirolimus, steroid avoidance arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
    <arm_group_label>Sirolimus, steroid avoidance arm</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African American recipient race

          -  Solitary cadaveric or living donor renal transplantation

          -  Age â‰¥18years at the time of transplantation

          -  Negative pregnancy serum test in females with childbearing potential

        Exclusion Criteria:

          -  Age &lt; 18 years at the time of transplantation

          -  Multi-organ transplant recipient

          -  Currently taking steroids

          -  White Blood Cell Count &lt; 3,000

          -  Platelet count &lt; 100,000

          -  Triglycerides &gt;400mg/dL

          -  Cholesterol &gt; 350 mg/dL

          -  Unwillingness to comply with study procedures

          -  Allergic reaction to sirolimus Allergy to polyclonal antilymphocyte drugs
             (Thymoglobulin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akinlolu Ojo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Health Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 20, 2017</results_first_submitted>
  <results_first_submitted_qc>February 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Akinlolu Ojo</investigator_full_name>
    <investigator_title>Emeritus Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus, Steroid Avoidance Arm</title>
          <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>From the 49 consented, 5 were not begun on treatment or removed very early on for clinical reasons, so they are not included in baseline data.</population>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus, Steroid Avoidance Arm</title>
          <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative One-year Acute Rejection Rates</title>
        <description>To test the efficacy of Sirolimus (SRL)-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: cumulative one-year acute rejection rates of the transplant</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus, Steroid Avoidance Arm</title>
            <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative One-year Acute Rejection Rates</title>
          <description>To test the efficacy of Sirolimus (SRL)-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: cumulative one-year acute rejection rates of the transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence margin 8% plus or minus 4.</non_inferiority_desc>
            <p_value>0.28</p_value>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>One-year Graft Survival</title>
        <description>To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year graft survival</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus, Steroid Avoidance Arm</title>
            <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Graft Survival</title>
          <description>To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year graft survival</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>Kaplan-Meier</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>One-year Patient Survival</title>
        <description>To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year patient survival</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus, Steroid Avoidance Arm</title>
            <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Patient Survival</title>
          <description>To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year patient survival</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Post Transplant Diabetes</title>
        <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is incidence of posttransplant diabetes mellitus</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus, Steroid Avoidance Arm</title>
            <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post Transplant Diabetes</title>
          <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is incidence of posttransplant diabetes mellitus</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug-treated Dyslipidemic Syndrome</title>
        <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is drug-treated dyslipidemic syndrome</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus, Steroid Avoidance Arm</title>
            <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Drug-treated Dyslipidemic Syndrome</title>
          <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is drug-treated dyslipidemic syndrome</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure Control</title>
        <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is number of people who had their blood pressure in the target control range with or without medication</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus, Steroid Avoidance Arm</title>
            <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure Control</title>
          <description>To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is number of people who had their blood pressure in the target control range with or without medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus, Steroid Avoidance Arm</title>
          <description>Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
Sirolimus: Thymoglobulin induction, sirolimus and no maintenance corticosteroid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Akinlolu Ojo, Professor of Medicine</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734 9364890</phone>
      <email>aojo@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

